Mumbai, December 10 (Udaipur Kiran): Shares of Zydus Lifesciences Ltd moved higher on the BSE on Wednesday after its arm entered into a strategic partnership with Formycon AG for a biosimilar of Keytruda. The stock was trading at Rs 932.90, up by 13.00 points or 1.41 per cent from its previous close of Rs 919.90.

The scrip opened at Rs 934.45 and touched an intraday high of Rs 937.00 and a low of Rs 925.55. A total of 3,491 shares were traded on the counter during the session.

The BSE Group ‘A’ stock, with a face value of Rs 1, had touched a 52-week high of Rs 1,059.00 on September 19, 2025, and a 52-week low of Rs 797.05 on April 7, 2025. Over the last one week, the stock moved between a high of Rs 944.10 and a low of Rs 912.75. The company’s current market capitalisation stands at Rs 94,133.19 crore.

Promoter holding in the company stands at 74.99 per cent, while institutional and non-institutional investors hold 18.20 per cent and 6.80 per cent, respectively.

Zydus Lifesciences’ wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates, has entered into a strategic partnership with Formycon AG for the exclusive licensing and supply of checkpoint inhibitor FYB206, a biosimilar of Keytruda (Pembrolizumab), in the USA and Canada markets.

Under the agreement, Formycon AG will be responsible for the development, registration, manufacturing and supply of the product, while Zydus Lifesciences Global FZE will handle the commercialization of FYB206 in the defined territories. The Biological License Application (BLA) is expected to be submitted to the USFDA in the near future, with the aim of making immunotherapy more affordable and accessible.

Zydus Lifesciences, formerly known as Cadila Healthcare, is an integrated pharmaceutical company engaged across the entire value chain, including research, development, production, marketing and distribution of pharmaceutical products.